D3 Pharma

D3 Bio is a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies to address significant unmet medical needs globally. The company's name, D3, represents its core mission: Discovery, Development, and Delivery of breakthrough medicines. Led by industry veterans with experience at major pharmaceutical firms like AstraZeneca, D3 Bio utilizes a data-driven approach to identify and optimize therapeutic candidates in the oncology space. Its pipeline features several promising programs, including small molecules and antibody-based therapies targeting well-validated pathways such as EGFR and KRAS, with multiple assets currently in Phase 1 and Phase 2 clinical trials.